TKT to Present at Wachovia Biotechnology Conference
December 09 2004 - 11:23AM
PR Newswire (US)
TKT to Present at Wachovia Biotechnology Conference CAMBRIDGE,
Mass., Dec. 9 /PRNewswire-FirstCall/ -- Transkaryotic Therapies,
Inc. (NASDAQ:TKTX) today announced that the company will present at
Wachovia Capital Markets' Ten for '05 Biotechnology Conference
being held at the Ritz Carlton, Central Park in New York on
December 16, 2004. The conference will feature ten companies
expected to report pivotal clinical trial results in 2005. David D.
Pendergast, Ph.D., Chief Operating Officer of TKT, will present an
overview of the company's AIM study (Assessment of I2S in MPS II)
at 9:30 a.m. Eastern Standard Time. The AIM study is a pivotal
trial evaluating iduronate-2-sulfatase (I2S), TKT's investigational
enzyme replacement therapy being development for the treatment of
Hunter syndrome. TKT expects top-line results from the AIM study in
June 2005, and, if positive, the company expects to submit
applications for marketing approval in both the United States and
Europe in the second half of 2005. A live audio webcast of this
presentation will be available at http://www.tktx.com/ on TKT's
Investor Information website under the Events category. A replay
will be available for approximately 30 days after the webcast.
About TKT Transkaryotic Therapies, Inc. is a biopharmaceutical
company primarily focused on researching, developing and
commercializing treatments for rare diseases caused by protein
deficiencies. Within this focus, the company markets Replagal(TM),
an enzyme replacement therapy for Fabry disease, and is developing
treatments for Hunter syndrome and Gaucher disease. In addition to
its focus on rare diseases, TKT intends to commercialize
Dynepo(TM), its Gene- Activated(R) erythropoietin product for
anemia related to kidney disease, in the European Union. TKT was
founded in 1988 and is headquartered in Cambridge, Massachusetts,
with additional operations in Europe, Canada and South America.
Additional information about TKT is available on the company's
website at http://www.tktx.com/. Gene-Activated(R) is a registered
trademark and Replagal(TM) is a trademark of Transkaryotic
Therapies, Inc. Dynepo(TM) is a trademark of Sanofi-Aventis SA. For
More Information Contact: Daniella M. Lutz Corporate Communications
Manager (617) 349-0205
http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
http://photoarchive.ap.org/ DATASOURCE: Transkaryotic Therapies,
Inc. CONTACT: Daniella M. Lutz, Corporate Communications Manager of
Transkaryotic Therapies, Inc., +1-617-349-0205 Web site:
http://www.tktx.com/ Company News On-Call:
http://www.prnewswire.com/comp/120657.html
Copyright
Transkaryotic Therapies (NASDAQ:TKTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Transkaryotic Therapies (NASDAQ:TKTX)
Historical Stock Chart
From Jul 2023 to Jul 2024